ASLN vs. CNSP, THAR, MYNZ, SNOA, MTNB, GLTO, MBIO, SNGX, MBRX, and RDHL
Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include CNS Pharmaceuticals (CNSP), Tharimmune (THAR), Mainz Biomed (MYNZ), Sonoma Pharmaceuticals (SNOA), Matinas Biopharma (MTNB), Galecto (GLTO), Mustang Bio (MBIO), Soligenix (SNGX), Moleculin Biotech (MBRX), and Redhill Biopharma (RDHL). These companies are all part of the "pharmaceutical products" industry.
ASLAN Pharmaceuticals vs. Its Competitors
CNS Pharmaceuticals (NASDAQ:CNSP) and ASLAN Pharmaceuticals (NASDAQ:ASLN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
CNS Pharmaceuticals' return on equity of -385.41% beat ASLAN Pharmaceuticals' return on equity.
CNS Pharmaceuticals has a beta of 2.58, indicating that its stock price is 158% more volatile than the S&P 500. Comparatively, ASLAN Pharmaceuticals has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 58.8% of ASLAN Pharmaceuticals shares are held by institutional investors. 0.1% of CNS Pharmaceuticals shares are held by insiders. Comparatively, 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
CNS Pharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 2,614.44%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than ASLAN Pharmaceuticals.
CNS Pharmaceuticals has higher earnings, but lower revenue than ASLAN Pharmaceuticals. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, CNS Pharmaceuticals had 1 more articles in the media than ASLAN Pharmaceuticals. MarketBeat recorded 1 mentions for CNS Pharmaceuticals and 0 mentions for ASLAN Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.75 beat ASLAN Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.
Summary
CNS Pharmaceuticals beats ASLAN Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
Get ASLAN Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASLN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ASLAN Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ASLN) was last updated on 7/5/2025 by MarketBeat.com Staff
